Zymeworks Management
Management criteria checks 2/4
Zymeworks' CEO is Ken Galbraith, appointed in Jan 2022, has a tenure of 3.83 years. total yearly compensation is $5.25M, comprised of 12.5% salary and 87.5% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $1.83M. The average tenure of the management team and the board of directors is 2.3 years and 2.1 years respectively.
Key information
Ken Galbraith
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 12.46% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up
Nov 18
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking
Sep 07Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On
Sep 02Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Aug 10There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price
Jun 18Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
May 14Zymeworks: Poised For Growth With Platform Validation
Apr 28We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely
Apr 16
Ziihera Launch And ZW251 IND Submission Will Broaden Treatment Options
Strategic focus on advanced programs and cost management aims to enhance resource efficiency and net margins through promising returns.Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13%
Mar 11Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price
Feb 28Zymeworks: Its Post-Approval Future
Feb 10Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
Dec 19Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
Dec 13Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking
Nov 08Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Nov 04Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$63m |
| Jun 30 2025 | n/a | n/a | -US$74m |
| Mar 31 2025 | n/a | n/a | -US$114m |
| Dec 31 2024 | US$5m | US$655k | -US$123m |
| Sep 30 2024 | n/a | n/a | -US$114m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$625k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$205m |
| Jun 30 2023 | n/a | n/a | US$186m |
| Mar 31 2023 | n/a | n/a | US$173m |
| Dec 31 2022 | US$7m | US$582k | US$124m |
| Sep 30 2022 | n/a | n/a | -US$224m |
| Jun 30 2022 | n/a | n/a | -US$237m |
| Mar 31 2022 | n/a | n/a | -US$240m |
| Dec 31 2021 | n/a | n/a | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$211m |
| Jun 30 2021 | n/a | n/a | -US$223m |
| Mar 31 2021 | n/a | n/a | -US$194m |
| Dec 31 2020 | n/a | n/a | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$215m |
| Jun 30 2020 | n/a | n/a | -US$173m |
| Mar 31 2020 | n/a | n/a | -US$163m |
| Dec 31 2019 | US$167k | n/a | -US$145m |
Compensation vs Market: Ken's total compensation ($USD5.25M) is about average for companies of similar size in the US market ($USD5.55M).
Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.
CEO
Ken Galbraith (62 yo)
Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 3.8yrs | US$5.25m | 0.11% $ 1.8m | |
| Executive VP and Chief Business & Financial Officer | 1.2yrs | US$2.91m | no data | |
| Acting Chief Investment Officer | no data | no data | no data | |
| Chief Scientific Officer | 3.3yrs | US$1.99m | 0.031% $ 527.3k | |
| Executive VP and Head of Technical & Manufacturing Operations | no data | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP | no data | no data | no data | |
| Senior Manager of Corporate Communications | no data | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data | |
| Vice President of Human Resources & DEI | 2.8yrs | no data | no data | |
| Executive VP & Chief Medical Officer | no data | no data | no data | |
| Senior Vice President of Process Sciences | 1.8yrs | no data | no data |
Experienced Management: ZYME's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 3.8yrs | US$5.25m | 0.11% $ 1.8m | |
| Independent Director | 5.7yrs | US$296.47k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | 6.4yrs | US$314.60k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.8yrs | US$810.23k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0.66% $ 11.2m | |
| Independent Director | 2.4yrs | US$306.47k | 0% $ 0 |
Experienced Board: ZYME's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 23:03 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymeworks Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |